nurulimab   Click here for help

GtoPdb Ligand ID: 12992

Synonyms: BCD-145 | BCD145
Immunopharmacology Ligand
Compound class: Antibody
Comment: Nurulimab (BCD-145) is a human IgG1 anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) monoclonal antibody. It blocks the interaction between CTLA4 and its ligands CD80 and CD86, which establishes an inhibitory immune checkpoint. Blocking this checkpoint offers therapeutic potential as this mechanism stimulates the immune system to destroy cancer cells.
No information available.
Summary of Clinical Use Click here for help
Nurulimab (BCD-145) is in clinical development. It is also being evaluated for efficacy in combination with the anti-PD-1 candidate prolgolimab (BCD-100). The combination of BCD-100 and BCD-145 is known as BCD-217.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03472027 Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma Phase 1 Interventional Biocad